{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:13:18Z","timestamp":1777043598691,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,2,14]],"date-time":"2012-02-14T00:00:00Z","timestamp":1329177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00520-012-1402-2","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T11:49:29Z","timestamp":1329133769000},"page":"2803-2809","source":"Crossref","is-referenced-by-count":6,"title":["Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting"],"prefix":"10.1007","volume":"20","author":[{"given":"Gerald M.","family":"Higa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miklos L.","family":"Auber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerry","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,14]]},"reference":[{"key":"1402_CR1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1996.14.2.671","volume":"14","author":"American Society of Clinical Oncology","year":"1996","unstructured":"American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671\u2013679","journal-title":"J Clin Oncol"},{"key":"1402_CR2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/bjc.2011.179","volume":"104","author":"J Wang","year":"2011","unstructured":"Wang J, Zhao Z, Barber B, Sherrill B, Peeters M, Wiezorek J (2011) A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer 104:1848\u20131853","journal-title":"Br J Cancer"},{"key":"1402_CR3","first-page":"CD003445","volume":"3","author":"N Ahmed","year":"2004","unstructured":"Ahmed N, Ahmedzai S, Vora V, Hillam S, Paz S (2004) Supportive care for patients with gastrointestinal cancer. Cochrane Database Syst Rev 3:CD003445","journal-title":"Cochrane Database Syst Rev"},{"key":"1402_CR4","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","volume":"18","author":"PJ Hesketh","year":"2010","unstructured":"Hesketh PJ, Aapro M, Street JC, Carides AD (2010) Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 18:1171\u20131177","journal-title":"Support Care Cancer"},{"key":"1402_CR5","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"15","author":"PJ Hesketh","year":"2003","unstructured":"Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin\u2014the Aprepitant Protocol 052 Study Group. J Clin Oncol 15:4112\u20134119","journal-title":"J Clin Oncol"},{"key":"1402_CR6","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2165\/00003495-199753020-00003","volume":"53","author":"C Veyrat-Follet","year":"1997","unstructured":"Veyrat-Follet C, Farinotti R, Palmer JL (1997) Physiology of chemotherapy-induced emesis and antiemetic therapy. Drugs 53:206\u2013234","journal-title":"Drugs"},{"issue":"Suppl 1","key":"1402_CR7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000227636","volume":"53","author":"LX Cubeddu","year":"1996","unstructured":"Cubeddu LX (1996) Serotonin mechanisms in chemotherapy-induced emesis in cancer patients. Oncology 53(Suppl 1):18\u201325","journal-title":"Oncology"},{"key":"1402_CR8","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.1998.16.3.1174","volume":"16","author":"J Latreille","year":"1998","unstructured":"Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174\u20131178","journal-title":"J Clin Oncol"},{"key":"1402_CR9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/oxfordjournals.annonc.a010798","volume":"9","author":"I Olver","year":"1996","unstructured":"Olver I, Paska W, Depierre A, Seitz JF, Stewart DJ, Goedhals L, McQuade B, McRae J, Wilkinson JR (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 9:945\u2013952","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"1402_CR10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0959-8049(05)80259-X","volume":"29A","author":"DR Gandara","year":"1993","unstructured":"Gandara DR, Harvey W, Moaghan GG, Perez EA, Hesketh PJ (1993) Delayed emesis following high-dose cisplatin: a double-blind randomized comparative trial of ondansetron (GR38032F) versus placebo. Eur J Cancer 29A(Suppl 1):35\u201338","journal-title":"Eur J Cancer"},{"key":"1402_CR11","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.11320","volume":"97","author":"SP Chawla","year":"2003","unstructured":"Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97:2290\u20132300","journal-title":"Cancer"},{"key":"1402_CR12","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1002\/cncr.10516","volume":"94","author":"S Belle Van","year":"2002","unstructured":"Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ (2002) Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758298 and MK-0869. Cancer 94:3032\u20133041","journal-title":"Cancer"},{"key":"1402_CR13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1200\/JCO.2001.19.6.1759","volume":"19","author":"D Campos","year":"2001","unstructured":"Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson LO, Carides AD, Gertz BJ (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759\u20131767","journal-title":"J Clin Oncol"},{"key":"1402_CR14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJM199901213400304","volume":"340","author":"RM Navari","year":"1999","unstructured":"Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz BJ (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 340:90\u2013195","journal-title":"N Engl J Med"},{"key":"1402_CR15","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/1097-0142(19931001)72:7<2239::AID-CNCR2820720729>3.0.CO;2-5","volume":"72","author":"OHG Wilder-Smith","year":"1993","unstructured":"Wilder-Smith OHG, Borgeat A, Chappuis P, Fathi M, Forni M (1993) Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 72:2239\u20132241","journal-title":"Cancer"},{"key":"1402_CR16","first-page":"38","volume":"7","author":"GM Higa","year":"2009","unstructured":"Higa GM, Auber ML, Altaha R, Kurian S, Hobbs G (2009) Concordance between substance P levels and antiemetic guidelines. J Support Oncol 7:38\u2013142","journal-title":"J Support Oncol"},{"key":"1402_CR17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1078155206072080","volume":"12","author":"GM Higa","year":"2006","unstructured":"Higa GM, Auber ML, Altaha R, Piktel D, Kurian S, Hobbs G, Landreth K (2006) 5-hydroxyindole acetic acid and substance P profiles in patients receiving emetogenic chemotherapy. J Oncol Pharm Pract 12:201\u2013209","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"1402_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00520-004-0699-x","volume":"13","author":"MG Kris","year":"2005","unstructured":"Kris MG, Hesketh PJ, Herrstedt J et al (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13(2):85\u201396","journal-title":"Support Care Cancer"},{"key":"1402_CR19","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1200\/JCO.2006.06.9591","volume":"24","author":"MJ Kris","year":"2006","unstructured":"Kris MJ, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guidelines for antiemetics in oncology. J Clin Oncol 24:2932\u20132947","journal-title":"J Clin Oncol"},{"key":"1402_CR20","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology; v.1.2007: antiemesis. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/antiemesis.pdf . Accessed 9 March 9"},{"key":"1402_CR21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1507\/endocrj1954.23.457","volume":"23","author":"C Yanaihara","year":"1976","unstructured":"Yanaihara C, Sato H, Hirohashi M, Sakagami M, Yamamoto K (1976) Substance P radioimmunoassay using N-a-tyrosyl-substance P and demonstration of the presence of substance P-like immunoreactivity in human blood and porcine tissue extracts. Endocrinol Jap 23:457\u2013463","journal-title":"Endocrinol Jap"},{"key":"1402_CR22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00280-010-1519-2","volume":"68","author":"T Takahashi","year":"2011","unstructured":"Takahashi T, Nakamura Y, Tsuya A, Murakami H, Endo M, Yamamoto N (2011) Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemother Pharmacol 68:653\u2013659","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl 1","key":"1402_CR23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000227637","volume":"53","author":"M Martin","year":"1996","unstructured":"Martin M (1996) The severity and pattern of emesis following different cytotoxic agents. Oncology 53(Suppl 1):26\u201331","journal-title":"Oncology"},{"key":"1402_CR24","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1200\/JCO.1995.13.9.2408","volume":"13","author":"RM Navari","year":"1995","unstructured":"Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC (1995) Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind randomized comparative trial of ondansetron versus placebo. J Clin Oncol 13:2408\u20132416","journal-title":"J Clin Oncol"},{"key":"1402_CR25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00520-009-0680-9","volume":"18","author":"BL Rapoport","year":"2010","unstructured":"Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423\u2013431","journal-title":"Support Care Cancer"},{"key":"1402_CR26","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","volume":"23","author":"DG Warr","year":"2005","unstructured":"Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822\u20132830","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1402-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-012-1402-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-012-1402-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:04:15Z","timestamp":1559081055000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-012-1402-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,14]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1007\/s00520-012-1402-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,14]]}}}